Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
The recently proposed Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) (Passamonti, Leukemia 2017) refines overall survival in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis (PPV, PET-MF) molecularly annotated for JAK2, CALR, and MPL mutations. We aimed to validate the prognostic utility of MYSEC-PM for PET / PPV-MF patients at MD Anderson Cancer Center (MDACC).
Conditions: Hematologic Diseases; Cachexia; Cancer; Leukemia; Myeloma; Lymphoma; Cancer Intervention: Other: whole-body electromyostimulation Sponsor: University of Erlangen-Nürnberg Medical School Recruiting
In a first, a national cancer organization has issued formal guidelines recommending exercise as part of cancer treatment, for all cancer patients. The Clinical Oncology Society of Australia (COSA) is very clear on the directive. Its recommendations are: Exercise should be embedded as part of standard practice in cancer care and viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment. All members of the multi-disciplinary cancer team should promote physical activity and help their patients adhere to exercise guidelines. Best practice cancer care should include referral to an accr...
Abstract Severe thrombocytopenia (≤50x109 platelets/L) due to hematological malignancy and intensive chemotherapy is associated with an increased risk of clinically significant bleeding. Since the bleeding risk is not linked to the platelet count only, other hemostatic factors must be involved. In 77 patients with acute leukemia, multiple myeloma or malignant lymphoma, who experienced chemotherapy-induced thrombocytopenia, we studied platelet function. Platelets from all patients - independent of disease or treatment type - were to a variable extent compromised in Ca2+ flux, integrin αIIbβ3 activatio...
Hodgkin ’s lymphoma (HL) patients have excellent outcomes but second cancers (SC) gain importance with survivorship. The Surveillance, Epidemiology and End Results database was utilized. The overall risk of SCs in HL patients declined over time but risk of SCs at several organ sites remained the same, nec essitating the need for ongoing targeted surveillance.
Conclusions: 18F-FDG PET/CT is useful in AL amyloidosis. It can help find the associated malignancy and detect 1/3 amyloid-related tissues or organs. In organs with no physiological distribution of 18F-FDG, the detection rate is especially high.
Conclusion: A novel methodology was used to quantify bone marrow activity portrayed by FDG-PET/CT for the whole skeleton of MM patients. The significant decrease in GSUVmean and GSUVmax uptake from pre- to post-treatment in the HDT group shows that the high dose treatment was likely successful to significantly decrease the cancer cells in the bone marrow of those patients.
Conclusion The patient-based sensitivity, specificity and accuracy of WB MRI including DWI were comparable with those of PET/MRI. On the other hand, the lesion-based sensitivities of WB MRI were relatively low, mainly because of the low detectability of small lymph node metastasis. The combination of T2WI and DWI showed acceptable detectability; however, the T1WI sequence showed no additional value to detect malignant lesions on both lesion- and patient-based sensitivities.
CONCLUSION. Our results show that metabolic parameters obtained on 18F-FDG PET/CT, even in at an early assessment, provide a reliable indication of treatment response in patients with HL under checkpoints inhibitors. Tumor burden modifications seem appreciable later in the course of immunotherapy, probably due to the re-activation of immune system and increased glucose consumption in the lymphocytes.
CONCLUSION: The frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data. PMID: 29748040 [PubMed - as supplied by publisher]
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children, with a peak incidence of 2 to 3 years, accounting for almost 30% of all cancers in this age group.It is well established that the identification of cytogenetic abnormalities is highly relevant for prognosis and therapeutic decisions in ALL.The purpose of this study is to define the frequency of recurrent chromosomal abnormalities of ALL in Moroccan patients referred exclusively to BIOLAB laboratory from the children hospital of Rabat over a period of 4 years and compare our findings to the literature.